EUVIMEDScopri EUVIMED
Multizentrische Studie

MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients

Stefanie Jilg iD, Juliana Schwaab, Katja Sockel, Carl C Crodel, Valeska Brueckl, Frank Stegelmann, Madlen Jentzsch iD, Daniel Sasca, Margarete Moyses, Stephan Fuhrmann, Daniel Gundel, Madlen Caduc and 4 more

Annals of Hematology · 2024-10 · 103 (10) · 4065-4077

DOI: 10.1007/s00277-024-05908-4 ↗

At a glance

Multizentrische Studie in Annals of Hematology, published online on 2024-07-29. Written by Stefanie Jilg and 15 co-authors. Institution: Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de. Major MEDLINE topics: Primary Myelofibrosis. Cited 11 times so far (Crossref); 32 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Abstract non disponibile.

Subjects

MeSH terms (MEDLINE)

Primary MyelofibrosisHumansMaleFemaleAgedMiddle AgedRetrospective StudiesPyrimidinesAged, 80 and overBenzamidesTreatment OutcomeJanus Kinase 2AdultJanus Kinase 1Pyrazines

Author keywords

AnemiaMoReLifeMomelotinibMyelofibrosisThrombocytopenia

Substances

PyrimidinesBenzamides4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamideJanus Kinase 2JAK2 protein, humanJanus Kinase 1Pyrazines

Authors and institutions

  • Onkologie Erding, Bajuwarenstr.3, Erding, Germany. stefanie.jilg@onkologie-erding.de.
  • Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. stefanie.jilg@onkologie-erding.de.
  • Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
  • Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany.
  • Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
  • Department of Hematology and Oncology, University Hospital Erlangen, Friedrich- Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

ORCID profiles: Stefanie Jilg, Madlen Jentzsch, Florian Heidel, Petro E Petrides

Cite

APA

Jilg, S., Schwaab, J., Sockel, K., Crodel, C. C., Brueckl, V., Stegelmann, F., Jentzsch, M., Sasca, D., Moyses, M., Fuhrmann, S., Gundel, D., Caduc, M., Teichmann, L. L., Heidel, F., Al-Ali, H. K., & Petrides, P. E. (2024). MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology, 103(10), 4065-4077. https://doi.org/10.1007/s00277-024-05908-4

Vancouver

Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, et al. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology. 2024;103(10):4065-4077. doi:10.1007/s00277-024-05908-4

BibTeX
@article{Jilg2024,
  author = {Jilg, Stefanie and Schwaab, Juliana and Sockel, Katja and Crodel, Carl C and Brueckl, Valeska and Stegelmann, Frank and Jentzsch, Madlen and Sasca, Daniel and Moyses, Margarete and Fuhrmann, Stephan and Gundel, Daniel and Caduc, Madlen and Teichmann, Lino L and Heidel, Florian and Al-Ali, Haifa K and Petrides, Petro E},
  title = {MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients},
  journal = {Annals of Hematology},
  year = {2024},
  volume = {103},
  number = {10},
  pages = {4065--4077},
  doi = {10.1007/s00277-024-05908-4}
}
Start for free →